JAX-NYSCF Conference Agenda
JAX-NYSCF Conference Agenda
Registration
Welcome Remarks
Susan L. Solomon Memorial Keynote Address
Elaine Fuchs, Ph.D.
Howard Hughes Medical Institute, The Rockefeller University
Tissue stem cells: Coping with stress and its consequences
Break
Aging & Rejuvenation
Juan Carlos Izpisua Belmonte, Ph.D.
Altos Labs
Break
Panel: Bridging Cellular and Animal Models
Moderator:
Mary Dickinson, Ph.D. – The Jackson Laboratory
California Institute for Regenerative Medicine
FUJIFILM Cellular Dynamics, Inc.
Complimentary Lunch
Neurodevelopment
Chair:
Vikram Khurana, M.D., Ph.D.
Brigham and Women’s Hospital,
NYSCF – Robertson Stem Cell Investigator Alum
Kristen Brennand, Ph.D.
Yale University; NYSCF – Robertson Stem Cell Investigator Alum
Gene x Environment Interactions in Brain Disease
University of California, San Francisco
Genomic insights into the development, evolution, and diseases of the developing human neocortex
Flora Vaccarino, M.D.Yale University
Reconstructing human development with somatic mutations
Break
Short Talks Selected from Abstracts
Break
Keynote I
Alex Meissner, Ph.D.
Max Planck Institute for Molecular Genetics;
NYSCF – Robertson Stem Cell Investigator Alum
Epigenetic regulation in development and disease
Poster Session
Registration
Opening Remarks
Announcement of Poster Awards
Keynote II
Massachusetts Institute of Technology
Break
Rare Disease and Gene Editing Advances
Chair: Frank Soldner, M.D. – Albert Einstein College of Medicine
Andrew Bassett, Ph.D.
Wellcome Sanger Institute
A CRISPR way to understand neurodegeneration
Cathleen (Cat) Lutz, Ph.D., M.B.A.
The Jackson Laboratory
Advances in gene editing—Is it all in the delivery?
Bill Skarnes, Ph.D.
The Jackson Laboratory
Break
Panel: New Approach Methods
Prabhakar Pandian, Ph.D.
GSK
National Institute on Aging
Complimentary Lunch
New Technologies for iPSCs
Kristin Baldwin, Ph.D.
Columbia University
Boston University
Bridging space, time, and causality in understanding cellular developmental trajectories
Break
Translational Cell Therapies
Gabi Belfort, M.D., Ph.D.
BlueRock Therapeutics
Continued evaluation of participants with Parkinson’s disease 3 years after Bemdaneprocel administration, and design of a Phase 3 trial.
Malin Parmar, Ph.D.
Lund University; NYSCF – Robertson Stem Cell Investigator Alum
STEM-PD: A stem cell-based therapy for Parkinson’s Disease
Neural Stem Cell Institute
From Stem Cell Discovery to the Clinic, Developing a Therapy
for Age-Related Macular Degeneration